Your browser doesn't support javascript.
loading
Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor.
Tsai, Alice; Wu, Shu-Pei; Haseltine, Eric; Kumar, Sanjeev; Moskowitz, Samuel M; Panorchan, Paul; Shah, Kushal.
Afiliação
  • Tsai A; Vertex Pharmaceuticals Incorporated, Boston, MA, USA. alice_tsai@vrtx.com.
  • Wu SP; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Haseltine E; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Kumar S; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Moskowitz SM; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Panorchan P; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Shah K; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
Pulm Ther ; 6(2): 287, 2020 Dec.
Article em En | MEDLINE | ID: mdl-32856286
The original version of this article unfortunately contained a mistake.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article